Status: Not yet recruiting
SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC
The entire treatment process is divided into two phases: Phase I SBRT combined with PD-1/CTLA-4 bispecific antibody (AK104) and Phase II AK104 single-agent maintenance therapy.
Participants needed: 25
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: The First People's Hospital of ChangzhouUpdated: Feb 17, 2023
Eligibility criteria
1. age ≥ 18 years. 2. patients enrolled must be eligible for PD-1 treatment-naïv...
1. pregnant gestational or lactating women. 2. those with a history of other mal...